ischemic heart disease

of 22 /22
Ischemic Heart Disease ....a major cause of mortality and morbidity worldwide

Upload: kassia

Post on 20-Feb-2016

33 views

Category:

Documents


0 download

DESCRIPTION

Ischemic Heart Disease . ....a major cause of mortality and morbidity worldwide. prognosis of patients with Acute Myocardial Infarction remains dismal. Stem Cell Therapy. The impact on: LEFT VENTRICULAR FUNCTION INFARCT SIZE LV DIMENSIONS ….remains unclear. - PowerPoint PPT Presentation

TRANSCRIPT

Page 1: Ischemic Heart  Disease

Ischemic Heart Disease

....a major cause of mortality and

morbidity worldwide

Page 2: Ischemic Heart  Disease

prognosis of patients with Acute Myocardial Infarction remains

dismal

Page 3: Ischemic Heart  Disease

Stem Cell Therapy

Page 4: Ischemic Heart  Disease

The impact on:• LEFT VENTRICULAR FUNCTION

• INFARCT SIZE• LV DIMENSIONS

….remains unclear.

IMPACT OF INTRACORONARY STEM CELL THERAPY IN

ACUTE MYOCARDIAL INFARCTION

Page 5: Ischemic Heart  Disease

OUTCOME OF INTRACORONARY STEM CELL THERAPY IN ACUTE MYOCARDIAL

INFARCTION: META-ANALYSIS OF RANDOMIZED

CONTROLLED TRIALSArvisminda Luz G. Fernandez, MD.

Chong Hua Hospital – Heart InstituteMay 24, 2012

Page 6: Ischemic Heart  Disease

General Objectives:To perform a meta-analysis on the

impact of intracoronary bone marrow stem cell therapy in acute myocardial infarction

OBJECTIVES

GENERAL OBJECTIVE

Page 7: Ischemic Heart  Disease

to assess if there is significant difference in the LV ejection fraction in patients with acute myocardial infarction who received bone marrow therapy versus control.

OBJECTIVES

to assess if there is significant difference in the LV end systolic volume in patients with acute myocardial infarction who received bone marrow therapy versus control.

SPECIFIC OBJECTIVES

Page 8: Ischemic Heart  Disease

REVIEW QUESTION AND STUDY PROTOCOL

“What is the outcome of bone marrow stem cell transplantation in patients with acute myocardial infarction following percutaneous coronary intervention?

This is a protocol-driven systematic review according to Quality of Reporting of Metaanalysis (QUOROM)

METHODS

Page 9: Ischemic Heart  Disease

INCLUSION CRITERIA

RCTs with comparison of intracoronary stem cell transplantation versus control in patients with acute myocardial infarction

Intention- to- treat analysis Follow-up ≥ 3 months from therapy

EXCLUSION CRITERIA

Use of cytokines for mobilization of BMCs Irretrievable or unclear data Treatment of old myocardial infarction (>14 days) Lack of control group Duplicate reports Ongoing or unpublished studies

METHODS

ELIGIBILITY CRITERIA

Page 10: Ischemic Heart  Disease

PubMed databases (2005-2010) Cochrane Central Registry of Controlled

Trials (2005-2010) Clinicaltrials.gov Registry (2005-2010) keywords: “stem cells, acute myocardial

infarction, randomized controlled trials”

METHODS

SEARCH STRATEGY

Page 11: Ischemic Heart  Disease

Study features extracted: outcome definitions. imaging modalities, patient baseline characteristics, and procedural dataPrimary endpoint:

- change in left ventricular ejection fraction (LVEF) from baseline to follow-up

Secondary endpoint: - change in left ventricular end systolic volumes

METHODS

DATA ABSTRACTION

Page 12: Ischemic Heart  Disease

The criteria by Jüni et al

METHODS

QUALITY OF ASSESSMENT

Page 13: Ischemic Heart  Disease

Dichotomous variables as proportion and percentages.

Continuous variables as mean ± standard deviation or median.

Meta-regression and sensitivity analyses to explore heterogeneity.

Statistical significance for hypothesis testing set at the 0.05, 2-tailed level.

 

 

METHODS

DATA ANALYSES

Page 14: Ischemic Heart  Disease

47Citations Retrieved

16Complete Articles

Assessed Based on Criteria

12Studies finally included in the

systematic review

31Titles/Abstracts non-

relevant

4- 1 used cytokines for BMC mobilization-2 had MI treatment > 14 days- 1 irretrievable data

REVIEW PROCESSMETHODS

Page 15: Ischemic Heart  Disease

Characteristics of Studies Included in the Meta-analysis

N = 934

RESULTS

Page 16: Ischemic Heart  Disease

Range of patients: 20-204

Follow-up Duration Range:

3-18 monthsAverage Timing of Cell Transplantation after

PCI :1-18 days

# of Stem cell Use:24.6±9.4x106

cells

Characteristics of Studies Included in the Meta-analysis

RESULTS

Page 17: Ischemic Heart  Disease

Quality of Assessment Scale for Randomized Controlled Trials Included in the Meta-Analysis

RESULTS

Page 18: Ischemic Heart  Disease

Forrest plot of unadjusted difference in mean (with 95% confidence intervals [CIs]) improvement in left ventricular ejection fraction (LVEF) in patients treated with bone marrow–derived cells (BMCs) compared with controls

Increase in LVEF of .72%

p value < 0.0001

RESULTS

Page 19: Ischemic Heart  Disease

Forrest plot of unadjusted difference in mean (with 95% confidence intervals [CIs]) improvement in left ventricular end systolic volume (LVESV) in patients treated with bone marrow–derived cells (BMCs) compared with controls

Standard Mean Difference

Decrease in LVESV of 0.425

mLp value <

0.0118

RESULTS

Page 20: Ischemic Heart  Disease

Intracoronary bone marrow stem cell resulted in: modest yet significant increase in LV ejection fraction significant decrease in LV end systolic volume ….in patients with acute myocardial infarction

RESULTS

Page 21: Ischemic Heart  Disease

DISCUSSION

Page 22: Ischemic Heart  Disease

INTRACORONARY BONE MARROW STEM CELL THERAPY INCREASE LVEF AND DECREASE LVESV IN ACUTE MYOCARDIAL

INFARCTION

THANK YOU and

GOOD DAY!